Omniox Funding: How Much Did They Raise & Key Investors

How Much Did Omniox Raise?
Funding & Key Investors

Omniox has successfully secured a major strategic investment, bringing its total capital accumulation to $35.7M. This latest infusion of $24.1M underscores the market confidence in the company's proprietary H-NOX platform technology. As the firm transitions through its current lifecycle stage, this financial backing serves as a critical catalyst for advancing its pipeline of oxygen delivery vehicles through the IND-stage regulatory process.

The company's growth trajectory, marked by a series of debt and private equity financing rounds dating back to 2014, reflects a sustained commitment to solving complex physiological challenges. By securing this latest round, Omniox is well-positioned to accelerate its clinical development programs and solidify its standing within the competitive biotherapeutics landscape.

What is Omniox?

Omniox

Business Services

Research & Development

Manufacturing

Omniox is a specialized biotherapeutics enterprise focused on the development of its proprietary H-NOX platform. The company engineers OMX oxygen delivery vehicles designed to address significant unmet medical needs by targeting pathologically hypoxic tissues. By restoring oxygen levels in compromised areas, these biologics aim to reverse disease pathology and improve patient outcomes. The firm operates at the intersection of advanced protein engineering and clinical medicine, positioning itself as a leader in the development of first-in-class and best-in-class therapeutic solutions for conditions driven by low oxygenation.

How much funding has Omniox raised?

Omniox has raised a total of $35.7M across 4 funding rounds:

2014

Private Equity

$6.6M

2016

Private Equity

$4.7M

2020

Debt

$350K

2026

Debt

$24.1M

Private Equity (2014): $6.6M, investors not publicly disclosed

Private Equity (2016): $4.7M, investors not publicly disclosed

Debt (2020): $350K supported by PPP

Debt (2026): $24.1M, investors not publicly disclosed

Key Investors in Omniox

PPP

Public-Private Partnership

Undisclosed Investors

What's next for Omniox?

With the recent influx of capital, Omniox is expected to prioritize the advancement of its OMX biologics through rigorous clinical trials and regulatory milestones. The strategic focus will likely center on scaling manufacturing capabilities and expanding the therapeutic application of its H-NOX technology to address a broader range of hypoxic-driven diseases. As the company moves deeper into the IND-stage, investors and industry stakeholders will be monitoring the firm's ability to translate its platform's potential into tangible clinical efficacy and long-term commercial viability.

See full Omniox company page

See More Financial Insights